All News

A 6-year analysis of the phase 3 STELLAR trial did not find any significant differences between total neoadjuvant treatment and concurrent chemoradiation in rectal cancer.

Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.

Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.

Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.

Scalp cooling may enhance patients’ quality of life when managing hair loss associated with cancer treatment.

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild to moderate severity.

Diverse dermatologic AEs, such as hair and nail toxicities, can be associated with various cancer treatments.

Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,

In the phase 3 ASCENT-03 trial, sacituzumab govitecan did not show an OS detriment vs chemotherapy in previously untreated metastatic triple-negative breast cancer.

Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen had a response.

Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.

Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.

Oncodermatology is critical in managing adverse effects from cancer treatments, specifically targeted therapies and immunotherapies.

Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment-emergent adverse effects or complications as well as strategies for managing them.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.

The safety profile of camrelizumab plus apatinib and chemotherapy in a phase 1 study aligns with prior reports of each agent.

The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.

Prostate-specific membrane antigen PET imaging has completely altered the landscape of prostate cancer detection and management. Read as several experts discuss the trajectory and growth of these agents.

Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.

Thoracic surgeon Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.

The European Commission is expected to approve the belantamab mafodotin combinations for this multiple myeloma population in the third quarter of 2025.

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.

In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.